Benenati, Stefano
Toma, Matteo
Canale, Claudia
Vergallo, Rocco
Bona, Roberta Della
Ricci, Davide
Canepa, Marco
Crimi, Gabriele
Santini, Francesco
Ameri, Pietro http://orcid.org/0000-0001-7167-7287
Porto, Italo
Funding for this research was provided by:
Università degli Studi di Genova
Article History
Accepted: 22 February 2021
First Online: 6 March 2021
Declarations
:
: Dr. Ameri reports personal fees from Novartis, personal fees from Astra Zeneca, personal fees from Vifor, personal fees from Daiichi-Sankyo, personal fees from Boehringer Ingelheim, personal fees from Janssen, personal fees from Merck Sharp & Dohme, and personal fees from GlaxoSmithKline, outside the submitted work; Dr. Porto reports grants and personal fees from AstraZeneca, personal fees from Daiichi Sankyo, personal fees from Terumo Corporation, personal fees from Biotronik, personal fees from Bayer, personal fees from Amgen, and personal fees and non-financial support from Abiomed, outside the submitted work; Dr. Canepa reports grants and personal fees from Pfizer, personal fees from Novartis, personal fees from Akcea Therapeutics, and personal fees from Sanofi Genzyme, outside the submitted work; Dr. Crimi reports personal fees from Philips healthcare, outside the submitted work; other authors have nothing to disclose.